03.10.2018 13:12:33

Alnylam Pharma Submits CTA To Initiate Phase 1/2 Study Of ALN-AAT02

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced it has submitted an Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Thomas Hoock, Vice President, Program Lead for ALN-AAT02 at Alnylam, stated: "We are also excited for ALN-AAT02 to enter the clinic as the first investigational RNAi therapeutic that will leverage the significant enhancements we have made to our GalNAc-siRNA conjugate platform. Pending feedback from the MHRA, we look forward to evaluating the safety, pharmacodynamics, and clinical activity of this molecule in a Phase 1/2 study in healthy volunteers and adults with alpha-1 liver disease, which we expect to initiate by year-end 2018."

Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Alnylam Pharmaceuticals Inc. 225,90 -0,22% Alnylam Pharmaceuticals Inc.